AR100859A1 - Polisacáridos y sus usos - Google Patents
Polisacáridos y sus usosInfo
- Publication number
- AR100859A1 AR100859A1 ARP150100534A ARP150100534A AR100859A1 AR 100859 A1 AR100859 A1 AR 100859A1 AR P150100534 A ARP150100534 A AR P150100534A AR P150100534 A ARP150100534 A AR P150100534A AR 100859 A1 AR100859 A1 AR 100859A1
- Authority
- AR
- Argentina
- Prior art keywords
- coli
- antigen
- protein
- detoxified
- carrier protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0066—Isolation or extraction of proteoglycans from organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una composición que comprende un bioconjugado de un antígeno O25B de E. coli acoplado covalentemente con una proteína portadora, en donde el antígeno O25B de E. coli comprende la estructura de la fórmula (1), en donde n es un número entero de entre 1 y 30. Reivindicación 11: Un método para inducir la producción de anticuerpos opsonofagocíticos en un sujeto que son específicos de Escherichia coli patogénico extraintestinal, que comprende la administración al sujeto de una cantidad efectiva de la composición de acuerdo con cualquiera de las reivindicaciones 1 - 8. Reivindicación 18: La célula huésped de acuerdo con la reivindicación 16 ó 17, en donde la proteína portadora se selecciona del grupo que consiste en Exotoxina A detoxificada de P. aeruginosa (EPA), CRM197, proteína de unión a maltosa (MBP), toxoide de difteria, toxoide tetánico, hemolisina A detoxificado de S. aureus, factor de aglutinación A, factor de aglutinación B, FimH de E. coli, FimHC de E. coli, enterotoxina lábil al calor de E. coli, variantes detoxificadas de enterotoxina lábil al calor de E. coli, subunidad de toxina B del cólera (CTB), toxina del cólera, variantes detoxificadas de toxina del cólera, proteína Sat de E. coli, el dominio pasajero de proteína Sat de E. coli, neumolisina de Streptococcus pneumoniae y sus variantes detoxificadas, AcrA de C. jejuni y glicoproteínas naturales de C. jejuni. Reivindicación 20: Un método de preparación de una proteína portadora N-glicosilada que comprende un antígeno O25B de E. coli, que comprende: a) cultivar la célula huésped de acuerdo con cualquiera de las reivindicaciones 16 - 19; y b) purificar una proteína portadora N-glicosilada que comprende antígeno O25B de E. coli.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943710P | 2014-02-24 | 2014-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100859A1 true AR100859A1 (es) | 2016-11-09 |
Family
ID=52589386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100534A AR100859A1 (es) | 2014-02-24 | 2015-02-23 | Polisacáridos y sus usos |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9700612B2 (es) |
| EP (1) | EP3110441B1 (es) |
| JP (2) | JP6276427B2 (es) |
| KR (1) | KR101855142B1 (es) |
| CN (1) | CN106535927B (es) |
| AR (1) | AR100859A1 (es) |
| AU (1) | AU2015220723C1 (es) |
| CA (1) | CA2940547C (es) |
| CL (1) | CL2016002123A1 (es) |
| DK (1) | DK3110441T5 (es) |
| EA (1) | EA035991B9 (es) |
| ES (1) | ES2978870T3 (es) |
| FI (1) | FI3110441T3 (es) |
| HR (1) | HRP20240847T1 (es) |
| HU (1) | HUE066507T2 (es) |
| IL (1) | IL247344B (es) |
| LT (1) | LT3110441T (es) |
| MX (1) | MX380438B (es) |
| NZ (1) | NZ723328A (es) |
| PH (1) | PH12016501671B1 (es) |
| PL (1) | PL3110441T3 (es) |
| PT (1) | PT3110441T (es) |
| RS (1) | RS65631B1 (es) |
| SG (1) | SG11201606889PA (es) |
| SI (1) | SI3110441T1 (es) |
| TW (1) | TWI639439B (es) |
| WO (1) | WO2015124769A1 (es) |
| ZA (1) | ZA201605858B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2945651T (pt) | 2013-01-17 | 2018-06-12 | Arsanis Biosciences Gmbh | Anticorpo específico para mdr e. coli |
| PL3110441T3 (pl) | 2014-02-24 | 2024-08-05 | Glaxosmithkline Biologicals S.A. | Nowatorski polisacharyd i jego zastosowania |
| JP2018515517A (ja) * | 2015-05-13 | 2018-06-14 | ユニバーシティ オブ ワシントンUniversity of Washington | 尿路病原性大腸菌感染病の処置と予防のための組成物および方法 |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| AR109621A1 (es) * | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| GB201711637D0 (en) * | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| US20190275134A1 (en) | 2018-03-12 | 2019-09-12 | Janssen Pharmaceuticals, Inc | Vaccines against urinary tract infections |
| CN108531439B (zh) * | 2018-04-16 | 2020-04-07 | 南京工业大学 | 一种大肠杆菌基因工程菌及其构建方法与应用 |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| IL286394B2 (en) | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | E. COLI O-antigen polysaccharide bioconjugates, methods for their production and methods for their use |
| IL286467B1 (en) | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them |
| CN110018253A (zh) * | 2019-04-15 | 2019-07-16 | 艾美卫信生物药业(浙江)有限公司 | 一种生物制品中游离蛋白含量的高效液相测定方法 |
| CN111855826B (zh) * | 2019-04-24 | 2022-09-16 | 岛津企业管理(中国)有限公司 | 破伤风类毒素或白喉类毒素的监测方法 |
| GB201908528D0 (en) * | 2019-06-13 | 2019-07-31 | Univ Dundee | Rhamnose-polysaccharides |
| EP4090363B1 (en) | 2020-01-16 | 2024-09-04 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
| WO2021165847A1 (en) * | 2020-02-21 | 2021-08-26 | Pfizer Inc. | Purification of saccharides |
| CN115605498A (zh) * | 2020-02-23 | 2023-01-13 | 辉瑞公司(Us) | 大肠杆菌组合物及其方法 |
| CN115697396A (zh) | 2020-06-18 | 2023-02-03 | 葛兰素史克生物有限公司 | 志贺氏菌-四价(Shigella4V)生物缀合物 |
| MX2022015734A (es) | 2020-06-25 | 2023-01-18 | Glaxosmithkline Biologicals Sa | Proteinas de exotoxina a modificadas. |
| JP7481585B2 (ja) | 2020-09-17 | 2024-05-10 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 多価ワクチン組成物及びその使用 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| PL4252003T3 (pl) * | 2020-11-30 | 2025-08-04 | Janssen Pharmaceuticals, Inc. | Sposób analityczny dla glikokoniugatów z zastosowaniem systemu oznaczania immunologicznego na bazie kapilar |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| TW202241929A (zh) | 2021-01-12 | 2022-11-01 | 美商詹森藥物公司 | FimH突變體、其組成物及其用途 |
| US12491237B2 (en) | 2021-02-16 | 2025-12-09 | Duke University | Vaccine compositions and methods for the treatment and prevention of urinary tract infections |
| WO2022208430A1 (en) | 2021-04-01 | 2022-10-06 | Janssen Pharmaceuticals, Inc. | Production of e. coli o18 bioconjugates |
| KR20240005684A (ko) | 2021-04-08 | 2024-01-12 | 얀센 파마슈티칼즈, 인코포레이티드 | 바이오컨쥬게이트 생산 방법 |
| WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
| US12014256B2 (en) | 2022-01-12 | 2024-06-18 | Dell Products L.P | Polysaccharide archival storage |
| CN114150005B (zh) * | 2022-02-09 | 2022-04-22 | 广州恩宝生物医药科技有限公司 | 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗 |
| JP2026500159A (ja) * | 2022-12-05 | 2026-01-06 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | バイオコンジュゲート組成物およびバイオコンジュゲート産生方法 |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| EP4478050A1 (en) | 2023-06-12 | 2024-12-18 | Janssen Pharmaceuticals, Inc. | Method for quantifying bound acetate in glycoconjugates |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422653D0 (en) | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| AUPM399594A0 (en) | 1994-02-21 | 1994-03-17 | Csl Limited | Antigenic preparation for treatment or prevention of helicobacter infection |
| FI102976B1 (fi) | 1994-02-28 | 1999-03-31 | Valtion Teknillinen | Menetelmä lisäkeittokemikaalien tuottamiseen ja käyttämiseen sulfaattiprosessissa |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| EP1278548A2 (en) | 2000-04-18 | 2003-01-29 | Endobiologics, Incorporated | Lipopolysaccharide-conjugate vaccine for sepsis treatment |
| RU2189253C1 (ru) | 2001-04-09 | 2002-09-20 | Государственный научный центр прикладной микробиологии | Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| DE60303591T2 (de) | 2002-03-07 | 2007-03-01 | Eidgenössische Technische Hochschule Zürich | System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| CN1324134C (zh) | 2003-12-22 | 2007-07-04 | 南开大学 | 对大肠杆菌o81型的o-抗原特异的核苷酸 |
| CN1950397B (zh) | 2004-03-30 | 2012-05-16 | Ns基因公司 | 生长因子NsG33的治疗用途 |
| PL2311972T3 (pl) | 2005-05-11 | 2015-08-31 | Eth Zuerich | Rekombinowane n-glikozylowane białka z komórek prokariotycznych |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| ES2376492T3 (es) | 2006-03-23 | 2012-03-14 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores. |
| JP4791866B2 (ja) | 2006-03-24 | 2011-10-12 | 国立大学法人秋田大学 | 下痢原性大腸菌感染症の判別に用いられる固相等 |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2009089396A2 (en) | 2008-01-08 | 2009-07-16 | Neose Technologies, Inc. | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| PL2257307T3 (pl) * | 2008-02-20 | 2018-11-30 | Glaxosmithkline Biologicals S.A. | Biokoniugaty wytworzone z rekombinowanych n-glikozylowanych białek z komórek prokariotycznych |
| BRPI1014774A2 (pt) | 2009-04-27 | 2019-04-16 | Immuron Limited | preparacao de imunoglobulina enriquecida anti-lps para uso no tratamento e/ou na profilaxia de um disturbio patologico |
| AU2010322454B2 (en) | 2009-11-19 | 2016-05-19 | Glaxosmithkline Biologicals S.A. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| DK3336225T3 (da) | 2010-07-16 | 2020-03-30 | Adimab Llc | Antistofbiblioteker |
| KR20140005892A (ko) | 2010-12-10 | 2014-01-15 | 머크 샤프 앤드 돔 코포레이션 | 면역원성 조성물의 진탕-유도된 응집을 완화시키는 신규한 제제 |
| WO2013034664A1 (en) * | 2011-09-06 | 2013-03-14 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
| US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
| BR112015004817A2 (pt) | 2012-09-10 | 2017-07-04 | Glycovaxyn Ag | bioconjugados compreendendo antígenos modificados e seus usos |
| SG11201502638YA (en) | 2012-10-12 | 2015-05-28 | Glycovaxyn Ag | Methods of host cell modification |
| EP2917351B1 (en) | 2012-11-07 | 2018-12-19 | GlaxoSmithKline Biologicals S.A. | Production of recombinant vaccine in e. coli by enzymatic conjugation |
| ES2750525T3 (es) | 2012-12-27 | 2020-03-26 | Glaxosmithkline Biologicals Sa | Procedimientos y composiciones relacionados con CRM197 |
| PT2945651T (pt) | 2013-01-17 | 2018-06-12 | Arsanis Biosciences Gmbh | Anticorpo específico para mdr e. coli |
| JP2016533719A (ja) | 2013-10-11 | 2016-11-04 | グリコヴァキシン アーゲー | 宿主細胞改変方法 |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| CN113388032A (zh) | 2014-02-06 | 2021-09-14 | X4制药(奥地利)有限责任公司 | 大肠杆菌特异性抗体序列 |
| PL3110441T3 (pl) | 2014-02-24 | 2024-08-05 | Glaxosmithkline Biologicals S.A. | Nowatorski polisacharyd i jego zastosowania |
| HUE057726T2 (hu) | 2014-12-30 | 2022-06-28 | Glaxosmithkline Biologicals Sa | Fehérje glikozilálására szolgáló készítmények és módszerek |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| IL286394B2 (en) | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | E. COLI O-antigen polysaccharide bioconjugates, methods for their production and methods for their use |
| IL286467B1 (en) | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them |
| FR3098334B1 (fr) | 2019-07-05 | 2021-07-23 | Airbus Operations Sas | Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef |
| WO2022208430A1 (en) | 2021-04-01 | 2022-10-06 | Janssen Pharmaceuticals, Inc. | Production of e. coli o18 bioconjugates |
-
2015
- 2015-02-23 PL PL15706459.3T patent/PL3110441T3/pl unknown
- 2015-02-23 RS RS20240696A patent/RS65631B1/sr unknown
- 2015-02-23 AR ARP150100534A patent/AR100859A1/es active IP Right Grant
- 2015-02-23 PT PT157064593T patent/PT3110441T/pt unknown
- 2015-02-23 WO PCT/EP2015/053739 patent/WO2015124769A1/en not_active Ceased
- 2015-02-23 HU HUE15706459A patent/HUE066507T2/hu unknown
- 2015-02-23 HR HRP20240847TT patent/HRP20240847T1/hr unknown
- 2015-02-23 DK DK15706459.3T patent/DK3110441T5/da active
- 2015-02-23 AU AU2015220723A patent/AU2015220723C1/en active Active
- 2015-02-23 US US14/628,844 patent/US9700612B2/en active Active
- 2015-02-23 LT LTEPPCT/EP2015/053739T patent/LT3110441T/lt unknown
- 2015-02-23 CN CN201580020077.8A patent/CN106535927B/zh active Active
- 2015-02-23 SI SI201532007T patent/SI3110441T1/sl unknown
- 2015-02-23 SG SG11201606889PA patent/SG11201606889PA/en unknown
- 2015-02-23 FI FIEP15706459.3T patent/FI3110441T3/fi active
- 2015-02-23 EA EA201691478A patent/EA035991B9/ru unknown
- 2015-02-23 CA CA2940547A patent/CA2940547C/en active Active
- 2015-02-23 MX MX2016011055A patent/MX380438B/es unknown
- 2015-02-23 KR KR1020167026424A patent/KR101855142B1/ko active Active
- 2015-02-23 NZ NZ723328A patent/NZ723328A/en unknown
- 2015-02-23 ES ES15706459T patent/ES2978870T3/es active Active
- 2015-02-23 EP EP15706459.3A patent/EP3110441B1/en active Active
- 2015-02-23 JP JP2016570184A patent/JP6276427B2/ja active Active
- 2015-02-24 TW TW104105953A patent/TWI639439B/zh active
-
2016
- 2016-08-18 IL IL247344A patent/IL247344B/en active IP Right Grant
- 2016-08-23 CL CL2016002123A patent/CL2016002123A1/es unknown
- 2016-08-23 ZA ZA2016/05858A patent/ZA201605858B/en unknown
- 2016-08-23 PH PH12016501671A patent/PH12016501671B1/en unknown
-
2017
- 2017-07-07 US US15/643,788 patent/US10441647B2/en active Active
-
2018
- 2018-01-11 JP JP2018002276A patent/JP6771499B2/ja active Active
-
2019
- 2019-10-11 US US16/599,900 patent/US10940192B2/en active Active
-
2021
- 2021-02-02 US US17/165,333 patent/US11738076B2/en active Active
-
2023
- 2023-04-24 US US18/305,948 patent/US12214029B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100859A1 (es) | Polisacáridos y sus usos | |
| BR112018003469A2 (pt) | composição, método para induzir uma resposta imune a e. coli patogênica extraintestinal, e, processo para produzir uma composição. | |
| PH12021550318A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| MX2020002557A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina. | |
| MX2020002556A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
| MX386692B (es) | Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos | |
| MX2020002555A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
| MX388869B (es) | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos. | |
| BR112018007812A2 (pt) | polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica. | |
| MX2016009468A (es) | Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos. | |
| AR092897A1 (es) | Composiciones inmunogenicas | |
| MX2016002386A (es) | Vacuna bacteriana y metodos para la fabricacion de la misma. | |
| ZA202103560B (en) | Multivalent pneumococcal polysaccharide-protein conjugate vaccine | |
| MA46661B1 (fr) | Formulations de vaccin glycoconjugué dirigé contre expec | |
| JOP20190038B1 (ar) | تركيب اقتراني من السكر المتعدد لكبسولة بكتيريا المكورات الرئوية وبروتين حامل واستخداماته | |
| MX2016000099A (es) | Vacunas sinteticas contra streptococcus pneumoniae tipo 1. | |
| PH12018501205A1 (en) | Synthetic vaccines against streptococcus pneumoniae serotype 2 | |
| AR105793A1 (es) | Métodos y composiciones para protección inmunológica contra e. coli patogénica extraintestinal | |
| AR114693A1 (es) | Vacunas contra infecciones intraabdominales | |
| AR125423A1 (es) | Vacunas contra infecciones del tracto urinario |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |